TrueMark Investments LLC Decreases Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

TrueMark Investments LLC reduced its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 7.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 42,127 shares of the company’s stock after selling 3,353 shares during the quarter. TrueMark Investments LLC’s holdings in Structure Therapeutics were worth $1,142,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in GPCR. Geode Capital Management LLC boosted its stake in shares of Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after acquiring an additional 312 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the last quarter. LPL Financial LLC boosted its position in Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock worth $311,000 after purchasing an additional 646 shares in the last quarter. Money Concepts Capital Corp grew its holdings in Structure Therapeutics by 4.2% in the fourth quarter. Money Concepts Capital Corp now owns 21,031 shares of the company’s stock valued at $570,000 after purchasing an additional 848 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after buying an additional 953 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $20.34 on Wednesday. The firm has a market cap of $1.17 billion, a PE ratio of -27.49 and a beta of -2.37. The firm has a 50 day simple moving average of $24.61 and a 200-day simple moving average of $31.51. Structure Therapeutics Inc. has a 1-year low of $19.39 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.